v-Fes antibody | knockout validation | Millipore OP02

This is a knockout-validated antibody summary, based on the publication "Comparative oncogenomics identifies tyrosine kinase FES as a tumor suppressor in melanoma", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

Antibody information

Rat monoclonal IgM

Company: Millipore

Antibody: v-Fes

Catalog number: OP02

Summary: Rat monoclonal IgM against v-Fes-transformed cells. Reacts with human, mouse and rat. Suitable for immunoprecipitation and neutralization studies.

Validation Method

Western blot

Sample

Fes+/+ or Fes–/– mouse melanoma lesions. Tissue samples were additionally homogenized with Precellys Homogenizer (Bertin Technologies) in protein lysis buffer (25 mM HEPES, pH 7.5, 0.3 M NaCl, 1.5 mM MgCl2 , 2 mM EDTA, 2 mM EGTA, 1 mM DTT, 1% Triton X-100, 10% glycerol, phosphatase/protease inhibitor cocktail).

Blocking agent

5% milk in TBS, 0.2%Tween-20.

Primary incubation

1:30,000 dilution.

Secondary incubation

HRP-conjugated secondary antibody (Cell Signaling Technology).

Detection

ECL Western blotting reagent (Thermo Scientific).

Figure

Western blot analysis of FES protein levels in Fes+/+ or Fes–/– melanoma lesions. Vinculin and GAPDH served as loading controls. Please see Figure 7c in the article [1].

References
  1. Olvedy M, Tisserand J, Luciani F, Boeckx B, Wouters J, Lopez S, et al. Comparative oncogenomics identifies tyrosine kinase FES as a tumor suppressor in melanoma.. J Clin Invest. 2017;127:2310-2325 pubmed publisher